Equity Profile

GILD

Gilead Sciences, Inc.

Health CareBiotechnology$160.4B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

Gilead Sciences Beats on EPS, Stock Down 1.64%

Metric	Actual	Expected	Surprise
EPS	$2.03	$1.91	+7.69%
Revenue	N/A	$6.9B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Gilead Sciences Beats on EPS, Stock Down 1.64%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$2.03	$1.91	+7.69%
Revenue	N/A	$6.9B	N/A

Management Commentary

Tone: Unknown

No transcript is on record for this earnings call, so the analysis is based solely on numerical results.

What It Means

Gilead Sciences reported better-than-expected earnings per share, but did not provide revenue figures or future guidance. The stock reacted negatively, declining by 1.64%, which may reflect investor concerns over the lack of revenue details and future outlook.

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases, particularly in the fields of HIV, liver diseases, and oncology....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Gilead is managing costs and generating income.

$1.91

Revenue

Total revenue reflects the company's sales performance and growth trajectory, which is crucial for investor confidence.

$6.9B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases, particularly in the fields of HIV, liver diseases, and oncology. With a market cap of $169 billion, Gilead plays a significant role in the healthcare sector, addressing critical health challenges and advancing treatment options.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.92%

Avg Stock Reaction

-0.05%

Last Quarter Recap

In Q4 2025, Gilead reported an EPS of $1.86, exceeding expectations by 1.92%. However, the stock dropped 2.93% the following day, indicating market caution despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Gilead to report solid earnings this quarter, with a consensus EPS of $1.91 and revenue of $6.9 billion. Investors will be closely watching for any signs of growth in key therapeutic areas.

Bull Case

If Gilead exceeds EPS and revenue expectations, it could signal strong demand for its products and a positive outlook for future growth, potentially boosting investor confidence.

Bear Case

Conversely, if Gilead misses estimates or provides weak guidance, it could raise concerns about its market position and future profitability, leading to a negative reaction.

Key Metrics to Watch

EPS

$1.91

Earnings per share is a key indicator of profitability and will show how well Gilead is managing costs and generating income.

Revenue

$6.9B

Total revenue reflects the company's sales performance and growth trajectory, which is crucial for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Gilead's EPS exceed the consensus estimate of $1.91?

A beat on EPS would reinforce confidence in Gilead's profitability and growth potential, impacting stock performance.

What guidance will Gilead provide regarding future revenue growth?

Future revenue guidance will be critical for investor sentiment, as it indicates the company's outlook in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Gilead's potential for revenue growth in emerging markets, where demand for its therapies is increasing.

Supporting Evidence

Recent insider selling may indicate a lack of confidence in the near-term performance, which could affect investor sentiment.

Options pricing suggests a larger move than historical averages, indicating heightened uncertainty that may not align with actual performance.

Key Risk

If Gilead's revenue growth in emerging markets exceeds expectations, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on Gilead's ability to maintain profitability and growth in a competitive biotechnology landscape.

Bull Confirmed If

Exceeding an EPS of $1.91 and revenue of $6.9 billion would confirm a strong performance.

Bear Confirmed If

Falling short of the consensus EPS and revenue expectations would signal potential challenges ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±4.88%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility.

Options are pricing ±4.9% while GILD has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

20.9%

Calls (683K)P/C Ratio: 0.63Puts (638K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$845,760.00

6,000 sh

2 insiders

Net

$845,760.00

Net selling

Most Active Insiders· 2 open-market trades

Chief Financial OfficerDickinson Andrew D
$422,880.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Gilead beats expectations, history suggests the stock could see a positive reaction, potentially around a 1.3% move upwards.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess future growth.

Miss

Should Gilead miss estimates, history indicates a potential drop, with an average reaction of around -0.18% when they beat.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-NJJosh GottheimerRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Details on revenue performance from key therapeutic areas.
3Management's outlook on market conditions and competitive landscape.
4Insights into cost management and operational efficiency.
5Any commentary on international market expansion efforts.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

FANGReported

Diamondback Energy, Inc.

RecapView

May4

OSISReported

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases, particularly in the fields of HIV, liver diseases, and oncology....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Gilead is managing costs and generating income.

$1.91

Revenue

Total revenue reflects the company's sales performance and growth trajectory, which is crucial for investor confidence.

$6.9B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.92%

Avg Stock Reaction

-0.05%

Last Quarter Recap

In Q4 2025, Gilead reported an EPS of $1.86, exceeding expectations by 1.92%. However, the stock dropped 2.93% the following day, indicating market caution despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Gilead exceeds EPS and revenue expectations, it could signal strong demand for its products and a positive outlook for future growth, potentially boosting investor confidence.

Bear Case

Conversely, if Gilead misses estimates or provides weak guidance, it could raise concerns about its market position and future profitability, leading to a negative reaction.

Key Metrics to Watch

EPS

$1.91

Earnings per share is a key indicator of profitability and will show how well Gilead is managing costs and generating income.

Revenue

$6.9B

Total revenue reflects the company's sales performance and growth trajectory, which is crucial for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Gilead's EPS exceed the consensus estimate of $1.91?

A beat on EPS would reinforce confidence in Gilead's profitability and growth potential, impacting stock performance.

What guidance will Gilead provide regarding future revenue growth?

Future revenue guidance will be critical for investor sentiment, as it indicates the company's outlook in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Gilead's potential for revenue growth in emerging markets, where demand for its therapies is increasing.

Supporting Evidence

Recent insider selling may indicate a lack of confidence in the near-term performance, which could affect investor sentiment.

Options pricing suggests a larger move than historical averages, indicating heightened uncertainty that may not align with actual performance.

Key Risk

If Gilead's revenue growth in emerging markets exceeds expectations, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on Gilead's ability to maintain profitability and growth in a competitive biotechnology landscape.

Bull Confirmed If

Exceeding an EPS of $1.91 and revenue of $6.9 billion would confirm a strong performance.

Bear Confirmed If

Falling short of the consensus EPS and revenue expectations would signal potential challenges ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±4.88%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility.

Options are pricing ±4.9% while GILD has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

20.9%

Calls (683K)P/C Ratio: 0.63Puts (638K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$845,760.00

6,000 sh

2 insiders

Net

$845,760.00

Net selling

Most Active Insiders· 2 open-market trades

Chief Financial OfficerDickinson Andrew D
$422,880.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Gilead beats expectations, history suggests the stock could see a positive reaction, potentially around a 1.3% move upwards.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess future growth.

Miss

Should Gilead miss estimates, history indicates a potential drop, with an average reaction of around -0.18% when they beat.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-NJJosh GottheimerRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Details on revenue performance from key therapeutic areas.
3Management's outlook on market conditions and competitive landscape.
4Insights into cost management and operational efficiency.
5Any commentary on international market expansion efforts.